DOCSLIB.ORG

SNAI1 Promotes the Cholangiocellular Phenotype, but Not Epithelial-Mesenchymal Transition, in a Murine Hepatocellular Carcinoma Model

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Author Manuscript Published OnlineFirst on August 5, 2019; DOI: 10.1158/0008-5472.CAN-18-3750 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 SNAI1 promotes the cholangiocellular phenotype, but not 2 epithelial-mesenchymal transition, in a murine hepatocellular carcinoma model 3 4 Meng Xu1,2,3,*, Jingxiao Wang3,4,*, Zhong Xu5, Rong Li6, Pan Wang3,7, Runze Shang3,8, 5 Antonio Cigliano9, Silvia Ribback10, Antonio Solinas11, Giovanni Mario. Pes 12, Katja 6 Evert9, Haichuan Wang3,13, Xinhua Song3, Shu Zhang3,14, Li Che3, Rosa Maria 7 Pascale12, Diego F. Calvisi9,10, Qingguang Liu1, Xin Chen3 8 9 1Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong 10 University, Xi'an Jiaotong University, Xi'an, PR China. 11 2Department of General Surgery, The Second Affiliated Hospital of Xi'an Jiaotong 12 University, Xi'an Jiaotong University, Xi'an, PR China 13 3Department of Bioengineering and Therapeutic Sciences and Liver Center, 14 University of California, San Francisco, CA, USA. 15 4School of Life Sciences, Beijing University of Chinese Medicine, Beijing, PR China 16 5Department of Gastroenterology, Guizhou Provincial People's Hospital, Medical 17 College of Guizhou University, Guiyang, PR China. 18 6Department of Anesthesiology, The Second Affiliated Hospital of Xi'an Jiaotong 19 University, Xi'an, PR China. 20 7Beijing Advanced Innovation Center for Food Nutrition and Human Health, College of 21 Food Science and Nutritional Engineering. 22 8Department of Hepatobiliary Surgery, Xi'jing Hospital, Air Force Military Medical 1 Downloaded from cancerres.aacrjournals.org on October 1, 2021. © 2019 American Association for Cancer Research. Author Manuscript Published OnlineFirst on August 5, 2019; DOI: 10.1158/0008-5472.CAN-18-3750 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 23 University, Xi'an, PR China 24 9Institute of Pathology, University Clinic of Regensburg, Regensburg, Germany 25 10Institute of Pathology, University of Greifswald, Greifswald, Germany 26 11Department of Biomedical Sciences, University of Sassari, Sassari, Italy 27 12Department of Medical, Surgical and Experimental Sciences, University of Sassari, 28 Sassari, Italy 29 13Liver Transplantation Division, Department of Liver Surgery, West China Hospital, 30 Sichuan University, Chengdu, PR China. 31 14Department of Radiation Oncology and Department of Head and Neck Oncology, 32 Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan 33 University, Chengdu, Sichuan, PR China. 34 35 *These authors contributed equally to the work 36 37 Running title：SNAI1 promotes cholangiocellular phenotype in vivo 38 39 Corresponding authors: 40 Diego F. Calvisi, M.D.; Institute of Pathology, University Clinic of Regensburg, 41 Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany. E-mail: 42 [email protected] 43 Qingguang Liu, M.D. Ph.D.; Department of Hepatobiliary Surgery, The First Affiliated 44 Hospital of Xi'an Jiaotong University, Xi'an 710061, PR China. Email: 2 Downloaded from cancerres.aacrjournals.org on October 1, 2021. © 2019 American Association for Cancer Research. Author Manuscript Published OnlineFirst on August 5, 2019; DOI: 10.1158/0008-5472.CAN-18-3750 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 45 [email protected] 46 47 Conflicts of interest statement 48 The authors declare that they have no conflict of interest. 49 50 Key words: hepatocellular carcinoma; SNAI1; cholangiocellular phenotype; 51 epithelial-mesenchymal transition; mouse model 52 3 Downloaded from cancerres.aacrjournals.org on October 1, 2021. © 2019 American Association for Cancer Research. Author Manuscript Published OnlineFirst on August 5, 2019; DOI: 10.1158/0008-5472.CAN-18-3750 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 53 Abstract 54 Hepatocellular carcinoma (HCC) is the most common type of liver cancer and has 55 limited treatment options. Snail family transcriptional repressor 1 (SNAI1) is a master 56 regulator of epithelial-mesenchymal transition (EMT) and has been implicated in HCC 57 initiation and progression. However, the precise role of SNAI1 and the way it 58 contributes to hepatocarcinogenesis have not been investigated in depth, especially 59 in vivo. Here, we analyzed the functional relevance of SNAI1 in promoting 60 hepatocarcinogenesis in the context of the AKT/c-Met driven mouse liver tumor model 61 (AKT/c-Met/SNAI1). Overexpression of SNAI1 did not accelerate AKT/c-Met-induced 62 HCC development or induce metastasis in mice. Elevated SNAI1 expression rather 63 led to the formation of cholangiocellular (CCA) lesions in the mouse liver, a phenotype 64 that was paralleled by increased activation of Yap and Notch. Ablation of Yap strongly 65 inhibited AKT/c-Met/SNAI-induced HCC and CCA development, whereas inhibition of 66 the Notch pathway specifically blocked the CCA-like phenotype in mice. Intriguingly, 67 overexpression of SNAI1 failed to induce EMT, indicated by strong E-cadherin 68 expression and lack of vimentin expression by AKT/c-Met/SNAI tumor cells. SNAI1 69 mRNA levels strongly correlated with the expression of CCA markers including SOX9, 70 CK19 and EPCAM, but not with EMT markers such as E-cadherin and ZO-1, in 71 human HCC samples. Overall, our findings suggest SNAI1 regulates the CCA-like 72 phenotype in hepatocarcinogenesis via regulation of Yap and Notch. 73 74 Significance 4 Downloaded from cancerres.aacrjournals.org on October 1, 2021. © 2019 American Association for Cancer Research. Author Manuscript Published OnlineFirst on August 5, 2019; DOI: 10.1158/0008-5472.CAN-18-3750 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 75 Findings report a new function of SNAI1 to promote cholangiocellular 76 transdifferentiation instead of epithelial-mesenchymal transition in hepatocellular 77 carcinoma. 78 79 Introduction 80 Liver cancer is one of the most common tumors and ranks second as a cause of 81 cancer mortality in the world (1, 2). Hepatocellular carcinoma (HCC) and 82 cholangiocarcinoma (CCA) are the two major histotypes of liver cancer. The diagnosis 83 for most HCC and CCA patients is achieved in the advanced stage of these tumors, 84 when only very limited treatment options are available (3, 4). Better understanding of 85 the mechanisms underlying HCC and CCA molecular pathogenesis is obviously of 86 high importance for the development of novel drugs able to treat efficiently these 87 deadly malignancies. 88 Recently, several studies have demonstrated the plasticity of liver cells. 89 Specifically, mounting evidence indicates that mature hepatocytes can transform into 90 cholangiocytes and vice versa (5-7). Besides the stem cell and cholangiocyte 91 compartments, intrahepatic CCA can derive from adult hepatocytes in mice (8, 9). 92 Studies in human HCC also identified a subset of HCC known as cholangiocellular 93 (CC) like HCC, characterized by the expression of biliary markers such as CK19 and 94 EPCAM (10, 11). In addition, mixed/combined HCC and CCA represent a liver cancer 95 entity in humans. Specifically, these mixed tumors have a prognosis similar to CCA 96 and worse than HCC. A recent genomic profile analysis indicated that mixed 5 Downloaded from cancerres.aacrjournals.org on October 1, 2021. © 2019 American Association for Cancer Research. Author Manuscript Published OnlineFirst on August 5, 2019; DOI: 10.1158/0008-5472.CAN-18-3750 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 97 HCC/CCA possess molecular features similar to HCC, even in the CCA component 98 (12). The precise mechanisms underlying this conversion remain poorly understood. 99 Recent studies suggest that the Hippo effector Yap and its downstream target Notch 100 are major regulators of cell fate in the liver (13). In mice, overexpression of the Hippo 101 kinase Lats2 prevents CC-like lesions formation in mouse liver tumor models induced 102 by activated AKT and N-Ras oncogenes (14). Furthermore, activated forms of Yap 103 cooperate with AKT to promote CCA development in mice (15-17). Notch signaling 104 has been identified as a major cascade downstream of Yap. Specifically, Yap directly 105 induces the expression of Notch2 and Jag1 genes (13, 18), and ablation of Notch2 106 completely prevents Yap dependent CC formation in vivo (19). Overall, these studies 107 suggest that, during hepatocarcinogenesis, Yap/Notch signaling cascade may 108 promote a CC-like phenotype in the liver. 109 Epithelial to mesenchymal transition (EMT) is a cellular process where epithelial 110 cells lose their cell polarity and transform into mesenchymal-like cells. In tumors, EMT 111 is frequently observed and associated with increased tumor cell proliferation, invasion, 112 and metastasis (20). EMT is recognized by the gain of expression of mesenchymal 113 marker, such as Vimentin and N-cadherin, as well as loss of epithelial markers, 114 including E-Cadherin, ZO-1 (TJP1), and Occludin, in tumor cells. It is well-established 115 that Snail family transcriptional repressor 1 (SNAI1) is a master regulator of EMT 116 during tumor progression (21). It induces EMT via binding to the three E-boxes of the 117 CDH1 (E-cadherin) promoter region, leading to the suppression of CDH1 expression 118
Recommended publications
  • Supplemental Figures

    Supplemental Figures

    A B Previously-induced Doxycycline-naïve survival (%) survival (%) Recurrence-free Recurrence-free Days following dox withdrawal Age C D Primary Recurrent ** Par-4 mRNA H2B-mCherry DAPI Primary Recurrent Supplemental Figure 1: Recurrent tumors are derived from primary tumors. A. Kaplan-Meier survival plot showing recurrent tumor-free survival in mice previously induced with doxycycline (n=30) or tumor-free survival in doxycycline-naïve mice (n=10). B. Kaplan-Meier survival plot showing recurrence-free survival following doxycycline withdrawal in a cohort of recipient mice with orthotopic tumors (n=5). C. Representative images (40x magnification) of primary and recurrent orthotopic tumors following injection of H2B-mCherry labeled primary tumor cell line #1 into recipient mice. D. qRT-PCR analysis of Par-4 transcripts from primary (n=5) and recurrent (n=5) orthotopic tumors. Significance determined by Student’s t-test. Error bars denote mean ± SEM. **p<0.01. A B 1 TWIST1 TWIST2 0.5 SNAI2 0 VIM -0.5 ZEB1 ZEB2 -1 SNAI1 PAWR Positively correlated Negatively correlated with Par-4 with Par-4 CDH1 CLDN7 CLDN4 CLDN3 KRT18 NES = -2.07335 q-value = 0.001129 KRT8 TWIST1 TWIST2 SNAI2 VIM ZEB1 ZEB2 SNAI1 PAWR CDH1 CLDN7 CLDN4 CLDN3 KRT18 KRT8 Marcotte, et al. C 1 SNAI1 0.5 TWIST1 TWIST2 0 VIM -0.5 SNAI2 -1 ZEB1 ZEB2 PAWR CDH1 KRT18 KRT8 CLDN7 CLDN3 CLDN4 SNAI1 TWIST1 TWIST2 VIM SNAI2 ZEB1 ZEB2 PAWR CDH1 KRT18 KRT8 CLDN7 CLDN3 CLDN4 TCGA, Cell 2015 Supplemental Figure 2: Par-4 expression is negatively correlated with EMT in human breast cancer. A.
  • Table S1 the Four Gene Sets Derived from Gene Expression Profiles of Escs and Differentiated Cells

    Table S1 the Four Gene Sets Derived from Gene Expression Profiles of Escs and Differentiated Cells

    Table S1 The four gene sets derived from gene expression profiles of ESCs and differentiated cells Uniform High Uniform Low ES Up ES Down EntrezID GeneSymbol EntrezID GeneSymbol EntrezID GeneSymbol EntrezID GeneSymbol 269261 Rpl12 11354 Abpa 68239 Krt42 15132 Hbb-bh1 67891 Rpl4 11537 Cfd 26380 Esrrb 15126 Hba-x 55949 Eef1b2 11698 Ambn 73703 Dppa2 15111 Hand2 18148 Npm1 11730 Ang3 67374 Jam2 65255 Asb4 67427 Rps20 11731 Ang2 22702 Zfp42 17292 Mesp1 15481 Hspa8 11807 Apoa2 58865 Tdh 19737 Rgs5 100041686 LOC100041686 11814 Apoc3 26388 Ifi202b 225518 Prdm6 11983 Atpif1 11945 Atp4b 11614 Nr0b1 20378 Frzb 19241 Tmsb4x 12007 Azgp1 76815 Calcoco2 12767 Cxcr4 20116 Rps8 12044 Bcl2a1a 219132 D14Ertd668e 103889 Hoxb2 20103 Rps5 12047 Bcl2a1d 381411 Gm1967 17701 Msx1 14694 Gnb2l1 12049 Bcl2l10 20899 Stra8 23796 Aplnr 19941 Rpl26 12096 Bglap1 78625 1700061G19Rik 12627 Cfc1 12070 Ngfrap1 12097 Bglap2 21816 Tgm1 12622 Cer1 19989 Rpl7 12267 C3ar1 67405 Nts 21385 Tbx2 19896 Rpl10a 12279 C9 435337 EG435337 56720 Tdo2 20044 Rps14 12391 Cav3 545913 Zscan4d 16869 Lhx1 19175 Psmb6 12409 Cbr2 244448 Triml1 22253 Unc5c 22627 Ywhae 12477 Ctla4 69134 2200001I15Rik 14174 Fgf3 19951 Rpl32 12523 Cd84 66065 Hsd17b14 16542 Kdr 66152 1110020P15Rik 12524 Cd86 81879 Tcfcp2l1 15122 Hba-a1 66489 Rpl35 12640 Cga 17907 Mylpf 15414 Hoxb6 15519 Hsp90aa1 12642 Ch25h 26424 Nr5a2 210530 Leprel1 66483 Rpl36al 12655 Chi3l3 83560 Tex14 12338 Capn6 27370 Rps26 12796 Camp 17450 Morc1 20671 Sox17 66576 Uqcrh 12869 Cox8b 79455 Pdcl2 20613 Snai1 22154 Tubb5 12959 Cryba4 231821 Centa1 17897
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
  • 4-6 Weeks Old Female C57BL/6 Mice Obtained from Jackson Labs Were Used for Cell Isolation

    4-6 Weeks Old Female C57BL/6 Mice Obtained from Jackson Labs Were Used for Cell Isolation

    Methods Mice: 4-6 weeks old female C57BL/6 mice obtained from Jackson labs were used for cell isolation. Female Foxp3-IRES-GFP reporter mice (1), backcrossed to B6/C57 background for 10 generations, were used for the isolation of naïve CD4 and naïve CD8 cells for the RNAseq experiments. The mice were housed in pathogen-free animal facility in the La Jolla Institute for Allergy and Immunology and were used according to protocols approved by the Institutional Animal Care and use Committee. Preparation of cells: Subsets of thymocytes were isolated by cell sorting as previously described (2), after cell surface staining using CD4 (GK1.5), CD8 (53-6.7), CD3ε (145- 2C11), CD24 (M1/69) (all from Biolegend). DP cells: CD4+CD8 int/hi; CD4 SP cells: CD4CD3 hi, CD24 int/lo; CD8 SP cells: CD8 int/hi CD4 CD3 hi, CD24 int/lo (Fig S2). Peripheral subsets were isolated after pooling spleen and lymph nodes. T cells were enriched by negative isolation using Dynabeads (Dynabeads untouched mouse T cells, 11413D, Invitrogen). After surface staining for CD4 (GK1.5), CD8 (53-6.7), CD62L (MEL-14), CD25 (PC61) and CD44 (IM7), naïve CD4+CD62L hiCD25-CD44lo and naïve CD8+CD62L hiCD25-CD44lo were obtained by sorting (BD FACS Aria). Additionally, for the RNAseq experiments, CD4 and CD8 naïve cells were isolated by sorting T cells from the Foxp3- IRES-GFP mice: CD4+CD62LhiCD25–CD44lo GFP(FOXP3)– and CD8+CD62LhiCD25– CD44lo GFP(FOXP3)– (antibodies were from Biolegend). In some cases, naïve CD4 cells were cultured in vitro under Th1 or Th2 polarizing conditions (3, 4).
  • CRB3 Antibody (Center) Blocking Peptide Synthetic Peptide Catalog # Bp17560c

    CRB3 Antibody (Center) Blocking Peptide Synthetic Peptide Catalog # Bp17560c

    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 CRB3 Antibody (Center) Blocking Peptide Synthetic peptide Catalog # BP17560c Specification CRB3 Antibody (Center) Blocking Peptide - CRB3 Antibody (Center) Blocking Peptide - Background Product Information This gene encodes a member of the Crumbs Primary Accession Q9BUF7 family ofproteins. This protein may play a role in epithelial cell polarityand is associated with tight junctions at the apical surface ofepithelial CRB3 Antibody (Center) Blocking Peptide - Additional Information cells. Alternate transcriptional splice variants,encoding different isoforms, have been characterized. [provided byRefSeq]. Gene ID 92359 CRB3 Antibody (Center) Blocking Peptide - Other Names References Protein crumbs homolog 3, CRB3 Pardossi-Piquard, R., et al. Biochemistry Format 46(48):13704-13710(2007)Fan, S., et al. J. Cell Peptides are lyophilized in a solid powder Biol. 178(3):387-398(2007)Fogg, V.C., et al. J. format. Peptides can be reconstituted in solution using the appropriate buffer as Cell. Sci. 118 (PT 13), 2859-2869 (2005) needed. :Lemmers, C., et al. Mol. Biol. Cell 15(3):1324-1333(2004)Roh, M.H., et al. J. Cell. Storage Sci. 116 (PT 14), 2895-2906 (2003) : Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. Precautions This product is for research use only. Not for use in diagnostic or therapeutic procedures. CRB3 Antibody (Center) Blocking Peptide - Protein Information Name CRB3 (HGNC:20237) Function Involved in the establishment of cell polarity in mammalian epithelial cells (PubMed:<a href="http://www.uniprot.org/c itations/12771187" target="_blank">12771187</a>, PubMed:<a href="http://www.uniprot.org/ci tations/14718572" target="_blank">14718572</a>).
  • Inhibition of FOXC2 Restores Epithelial Phenotype and Drug Sensitivity in Prostate Cancer Cells with Stem-Cell Properties

    Inhibition of FOXC2 Restores Epithelial Phenotype and Drug Sensitivity in Prostate Cancer Cells with Stem-Cell Properties

    OPEN Oncogene (2016) 35, 5963–5976 © 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved 0950-9232/16 www.nature.com/onc ORIGINAL ARTICLE Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties AN Paranjape1,10, R Soundararajan1,10, SJ Werden1, R Joseph1, JH Taube1, H Liu1, J Rodriguez-Canales1, N Sphyris1, I Wistuba1, N Miura2, J Dhillon3, N Mahajan3, K Mahajan3, JT Chang4, M Ittmann5, SN Maity6, C Logothetis6, DG Tang7 and SA Mani1,8,9 Advanced prostate adenocarcinomas enriched in stem-cell features, as well as variant androgen receptor (AR)-negative neuroendocrine (NE)/small-cell prostate cancers are difficult to treat, and account for up to 30% of prostate cancer-related deaths every year. While existing therapies for prostate cancer such as androgen deprivation therapy (ADT), destroy the bulk of the AR- positive cells within the tumor, eradicating this population eventually leads to castration-resistance, owing to the continued survival of AR-/lo stem-like cells. In this study, we identified a critical nexus between p38MAPK signaling, and the transcription factor Forkhead Box Protein C2 (FOXC2) known to promote cancer stem-cells and metastasis. We demonstrate that prostate cancer cells that are insensitive to ADT, as well as high-grade/NE prostate tumors, are characterized by elevated FOXC2, and that targeting FOXC2 using a well-tolerated p38 inhibitor restores epithelial attributes and ADT-sensitivity, and reduces the shedding of circulating tumor cells in vivo with significant shrinkage in the tumor mass. This study thus specifies a tangible mechanism to target the AR-/lo population of prostate cancer cells with stem-cell properties.
  • CRB3 Polyclonal Antibody Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP55396

    CRB3 Polyclonal Antibody Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP55396

    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 CRB3 Polyclonal Antibody Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP55396 Specification CRB3 Polyclonal Antibody - Product Information Application WB, IHC-P, IHC-F, IF, ICC Primary Accession Q9BUF7 Host Rabbit Clonality Polyclonal Calculated MW 12854 CRB3 Polyclonal Antibody - Additional Information Gene ID 92359 Other Names Protein crumbs homolog 3, CRB3 (<a href= "http://www.genenames.org/cgi-bin/gene_sy mbol_report?hgnc_id=20237" target="_blank">HGNC:20237</a>) Format 0.01M TBS(pH7.4) with 1% BSA, 0.09% (W/V) sodium azide and 50% Glyce Storage Store at -20 ℃ for one year. Avoid repeated freeze/thaw cycles. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 ℃. CRB3 Polyclonal Antibody - Protein Information Name CRB3 (HGNC:20237) Function Involved in the establishment of cell polarity in mammalian epithelial cells (PubMed:<a href="http://www.uniprot.org/c itations/12771187" target="_blank">12771187</a>, PubMed:<a href="http://www.uniprot.org/ci tations/14718572" target="_blank">14718572</a>). Regulates the morphogenesis of tight Page 1/2 10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 junctions (PubMed:<a href="http://www.uni prot.org/citations/12771187" target="_blank">12771187</a>, PubMed:<a href="http://www.uniprot.org/ci tations/14718572" target="_blank">14718572</a>). Involved in promoting phosphorylation and cytoplasmic retention of transcriptional coactivators YAP1 and WWTR1/TAZ which leads to suppression of TGFB1-dependent transcription of target genes such as CCN2/CTGF, SERPINE1/PAI1, SNAI1/SNAIL1 and SMAD7 (By similarity).
  • SNAI1 Expression in Colon Cancer Related with CDH1 and VDR Downregulation in Normal Adjacent Tissue

    SNAI1 Expression in Colon Cancer Related with CDH1 and VDR Downregulation in Normal Adjacent Tissue

    Oncogene (2009) 28, 4375–4385 & 2009 Macmillan Publishers Limited All rights reserved 0950-9232/09 $32.00 www.nature.com/onc ORIGINAL ARTICLE SNAI1 expression in colon cancer related with CDH1 and VDR downregulation in normal adjacent tissue C Pen˜a1,7, JM Garcı´a1,7, MJ Larriba2, R Barderas3,IGo´mez1, M Herrera1, V Garcı´a1, J Silva1, GDomı´nguez1, R Rodrı´guez4, J Cuevas5, AG de Herreros6, JI Casal3, A Mun˜oz2 and F Bonilla1 1Department of Medical Oncology, Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain; 2Instituto de Investigaciones Biome´dicas ‘Alberto Sols’, Consejo Superior de Investigaciones Cientı´ficas-Universidad Auto´noma de Madrid, Madrid, Spain; 3Functional Proteomics Laboratory, Centro de Investigaciones Biolo´gicas (CIB-CSIC), Madrid, Spain; 4Department of Pathology, Hospital Virgen de la Salud, Toledo, Spain; 5Department of Pathology, Hospital General Universitario, Guadalajara, Spain and 6Unitat de Biologı´a Cellular i Molecular, Institut Municipal d’Investigacio´ Me`dica, Universitat Pompeu Fabra, Barcelona, Spain SNAI1, ZEB1, E-cadherin (CDH1), and vitamin D Introduction receptor (VDR) genes regulate the epithelial–mesen- chymal transition (EMT) that initiates the invasion Numerous studies have focused on the function of process of many tumor cells. We hypothesized that this genetic abnormalities in various cancers, but very few of process could also affect the behavior of normal cells these analyzed their importance in normal tissue adjacent to the tumor. To verify this hypothesis, the adjacent to tumors. Loss of heterozygosity (LOH) or expression level of these genes was determined by allele imbalances (AI) at various chromosomal loci have quantitative RT–PCR in tumor, normal adjacent, and been observed in normal tissue adjacent to tumor in normal distant tissues from 32 colorectal cancer (CC) breast and bladder cancer patients (Deng et al., 1996; patients.
  • Ctbp2 Is an Independent Prognostic Marker That Promotes GLI1 Induced Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma

    Ctbp2 Is an Independent Prognostic Marker That Promotes GLI1 Induced Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma

    www.impactjournals.com/oncotarget/ Oncotarget, SupplementaryOncotarget, Materials Vol. 6, 2015No.6 CtBP2 is an independent prognostic marker that promotes GLI1 induced epithelial-mesenchymal transition in hepatocellular carcinoma Xin Zheng1,*, Tao Song1,*, Changwei Dou1, Yuli Jia1, Qingguang Liu1 1Department of Hepatobiliary Surgery, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi 710061, China *These authors have contributed equally to this work Correspondence to: Qingguang Liu, e-mail: [email protected] Keywords: C-terminal binding protein 2, CtBP2, GLI family zinc finger 1, GLI1, Snail Family Zinc Finger 1, epithelial-mesenchymal transition, EMT, Hepatocellular carcinoma, HCC Received: November 12, 2014 Accepted: December 15, 2014 Published: February 19, 2015 ABSTRACT C-terminal binding protein 2 (CtBP2) is a transcriptional co-repressor that promotes cancer cell migration and invasion by inhibiting multiple tumor suppressor genes that contribute to cell mobility and adhesion. In this investigation, we showed thatCtBP2 expression was increased significantly in HCC tissues when compared to matched normal adjacent liver tissues. We also showed that CtBP2 expression is associated with worse HCC patient prognosis after liver resection. CtBP2 over- expression induced epithelial-mesenchymal transition (EMT) in Huh7 cells and, correspondingly, silencing CtBP2 suppressed EMT in MHCC97H cells. ChIP assays revealed that GLI1 increased CtBP2 transcription by directly binding its promoter. Furthermore, interaction of CtBP2 and Snail Family Zinc Finger 1 (SNAI1), both of which were found to be positively regulated by GLI1, was confirmed by Co-IP assay. SNAI1 knockdown revealed that SNAI1 was essential for CtBP2 induction of the EMT phenotype of HCC cells, and CtBP2 knockdown reversed GLI1-SNAI1 driven EMT in Huh7 cells.
  • Fig1-13Tab1-5.Pdf

    Fig1-13Tab1-5.Pdf

    Supplementary Information Promoter hypomethylation of EpCAM-regulated bone morphogenetic protein genes in advanced endometrial cancer Ya-Ting Hsu, Fei Gu, Yi-Wen Huang, Joseph Liu, Jianhua Ruan, Rui-Lan Huang, Chiou-Miin Wang, Chun-Liang Chen, Rohit R. Jadhav, Hung-Cheng Lai, David G. Mutch, Paul J. Goodfellow, Ian M. Thompson, Nameer B. Kirma, and Tim Hui-Ming Huang Tables of contents Page Table of contents 2 Supplementary Methods 4 Supplementary Figure S1. Summarized sequencing reads and coverage of MBDCap-seq 8 Supplementary Figure S2. Reproducibility test of MBDCap-seq 10 Supplementary Figure S3. Validation of MBDCap-seq by MassARRAY analysis 11 Supplementary Figure S4. Distribution of differentially methylated regions (DMRs) in endometrial tumors relative to normal control 12 Supplementary Figure S5. Network analysis of differential methylation loci by using Steiner-tree analysis 13 Supplementary Figure S6. DNA methylation distribution in early and late stage of the TCGA endometrial cancer cohort 14 Supplementary Figure S7. Relative expression of BMP genes with EGF treatment in the presence or absence of PI3K/AKT and Raf (MAPK) inhibitors in endometrial cancer cells 15 Supplementary Figure S8. Induction of invasion by EGF in AN3CA and HEC1A cell lines 16 Supplementary Figure S9. Knockdown expression of BMP4 and BMP7 in RL95-2 cells 17 Supplementary Figure S10. Relative expression of BMPs and BMPRs in normal endometrial cell and endometrial cancer cell lines 18 Supplementary Figure S11. Microfluidics-based PCR analysis of EMT gene panel in RL95-2 cells with or without EGF treatment 19 Supplementary Figure S12. Knockdown expression of EpCAM by different shRNA sequences in RL95-2 cells 20 Supplementary Figure S13.
  • Supplementary Table 1

    Supplementary Table 1

    Supplementary Table 1. 492 genes are unique to 0 h post-heat timepoint. The name, p-value, fold change, location and family of each gene are indicated. Genes were filtered for an absolute value log2 ration 1.5 and a significance value of p ≤ 0.05. Symbol p-value Log Gene Name Location Family Ratio ABCA13 1.87E-02 3.292 ATP-binding cassette, sub-family unknown transporter A (ABC1), member 13 ABCB1 1.93E-02 −1.819 ATP-binding cassette, sub-family Plasma transporter B (MDR/TAP), member 1 Membrane ABCC3 2.83E-02 2.016 ATP-binding cassette, sub-family Plasma transporter C (CFTR/MRP), member 3 Membrane ABHD6 7.79E-03 −2.717 abhydrolase domain containing 6 Cytoplasm enzyme ACAT1 4.10E-02 3.009 acetyl-CoA acetyltransferase 1 Cytoplasm enzyme ACBD4 2.66E-03 1.722 acyl-CoA binding domain unknown other containing 4 ACSL5 1.86E-02 −2.876 acyl-CoA synthetase long-chain Cytoplasm enzyme family member 5 ADAM23 3.33E-02 −3.008 ADAM metallopeptidase domain Plasma peptidase 23 Membrane ADAM29 5.58E-03 3.463 ADAM metallopeptidase domain Plasma peptidase 29 Membrane ADAMTS17 2.67E-04 3.051 ADAM metallopeptidase with Extracellular other thrombospondin type 1 motif, 17 Space ADCYAP1R1 1.20E-02 1.848 adenylate cyclase activating Plasma G-protein polypeptide 1 (pituitary) receptor Membrane coupled type I receptor ADH6 (includes 4.02E-02 −1.845 alcohol dehydrogenase 6 (class Cytoplasm enzyme EG:130) V) AHSA2 1.54E-04 −1.6 AHA1, activator of heat shock unknown other 90kDa protein ATPase homolog 2 (yeast) AK5 3.32E-02 1.658 adenylate kinase 5 Cytoplasm kinase AK7
  • Genome Editing of the SNAI1 Gene in Rhabdomyosarcoma: a Novel Model for Studies of Its Role

    Genome Editing of the SNAI1 Gene in Rhabdomyosarcoma: a Novel Model for Studies of Its Role

    cells Article Genome Editing of the SNAI1 Gene in Rhabdomyosarcoma: A Novel Model for Studies of Its Role Aleksandra Ulman 1, Klaudia Skrzypek 1 , Paweł Konieczny 1, Claudio Mussolino 2,3, Toni Cathomen 2,3 and Marcin Majka 1,* 1 Department of Transplantation, Faculty of Medicine, Institute of Pediatrics, Jagiellonian University Medical College, 30-663 Cracow, Poland; [email protected] (A.U.); [email protected] (K.S.); [email protected] (P.K.) 2 Institute for Transfusion Medicine and Gene Therapy, Medical Center – University of Freiburg, 79106 Freiburg, Germany; [email protected] (C.M.); [email protected] (T.C.) 3 Center for Chronic Immunodeficiency, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany * Correspondence: [email protected]; Tel.: +48-12-659-15-93 Received: 31 March 2020; Accepted: 22 April 2020; Published: 28 April 2020 Abstract: Genome editing (GE) tools and RNA interference technology enable the modulation of gene expression in cancer research. While GE mediated by clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 or transcription activator-like effector nucleases (TALEN) activity can be used to induce gene knockouts, shRNA interacts with the targeted transcript, resulting in gene knockdown. Here, we compare three different methods for SNAI1 knockout or knockdown in rhabdomyosarcoma (RMS) cells. RMS is the most common sarcoma in children and its development has been previously associated with SNAI1 transcription factor activity. Toinvestigate the role of SNAI1 in RMS development, we compared CRISPR/Cas9, TALEN, and shRNA tools to identify the most efficient tool for the modulation of SNAI1 expression with biological effects.